<DOC>
	<DOCNO>NCT01421472</DOCNO>
	<brief_summary>To demonstrate whether addition MM-121 paclitaxel effective treatment paclitaxel alone , administered part neoadjuvant treatment Her2 negative locally advance operable breast cancer patient .</brief_summary>
	<brief_title>A Trial Preoperative MM-121 With Paclitaxel HER2-negative Breast Cancer</brief_title>
	<detailed_description>This multicenter , open-label , randomize , Phase II study preoperative MM-121 paclitaxel HER2-negative breast cancer . Patients randomize receive paclitaxel without MM-121 12 week follow 4 cycle doxorubicin plus cyclophosphamide subsequent surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histological confirmation ER positive , HER2 negative invasive breast cancer ( Group 1 ) invasive triplenegative breast cancer ( Group 2 ) Free metastatic disease ≥ 18 year old Female Had prior treatment cancer Eligible treatment paclitaxel , doxorubicin cyclophosphamide Have history severe allergic reaction paclitaxel drug formulate Cremaphor® EL Are pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Her2 negative</keyword>
	<keyword>Her2 non-overexpressing</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>MM-121</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>